As a young scientist, Dr. Stanislaw Burzynski isolated various peptides (amino acid chains that are necessary for forming proteins) from human urine, and discovered that they are very effective in suppressing the growth of certain types of cancer. They belong to the arsenal of the body’s biochemical defense system. They do not destroy the defective cells, rather they correct them or reprogram them, they carry good information to the abnormal cells, and tell them how they can develop normally. It has been determined that people with cancer only have 2-3% of the normal number of these peptides. For more than 30 years Dr. Burzynski has been separating 5 different antineoplastons from human urine, these are substances that act against a neoplasm (an abnormal tissue change) – such as against a tumor. His explanation for this is that these molecules, viewed on a genetic level have a strong anti-cancer effect. Particularly they stimulate the activities of “tumor suppressing genes”. Tumor suppressing genes are genes that switch off the activities of certain oncogenes (genes that support tumor growth). Thus they prevent cells from multiplying into a tumor in an uncontrolled manner. According to this theory cancer is the result of an antineoplaston deficit. Supported by his scientific publications Dr. Burzynski was able to obtain funding from the National Cancer Institute (NCI) in the USA, in 1974. In 1977 he published the results of a study with 21 advanced stage tumor and leukemia patients, for whom there were no chances of survival according to conventional treatment methods. In a period of 9 months, four patients had a complete remission, and 4 others had partial remissions (tumor reduction of more than 50%). For 6 patients the illness stabilized – it neither progressed nor went into remission. 2 patients stopped the treatment after their tumors were reduced by less than 50%. Only 5 patients died as a result of their original illness. Dr. Burzynski was convinced after this study that his antineoplaston treatment could save the lives of people with cancer. Because the NCI funding ran out at this time, Dr. Burzynski decided to finance his research himself, and founded his independent cancer treatment center (Burzynski Research Institute) and started charging his patients for his, “experimental treatment”, as he called it then. Thanks to these first patients he was able to survive the long years of research and development of the antineoplastons. Since the early 1970s Dr. Burzynski faced bitter attacks from the allopathic establishment, until the US Supreme Court ruled that he could treat patients. His scientific studies and records were simply too clear to be refuted by the FDA (Food and Drug Administration). In March 1990, at the 9th International Symposium on the “Future Trends in Chemotherapy” Dr. Dvorit Samid, declared that the antineoplaston AS2-1 sustainably suppresses the activity of oncogenes, as well as proliferation of malignant cells, however without being toxic for normal cells. According to scientific reports that were presented at the 86th annual convention of the “American Association for Cancer Research” in March 1995, it was recognizable that Dr. Burzynski’s antineoplastons increased the activities of tumor-suppression genes. Today Dr. Burzynski produces his antineoplastons in a production facility, that is approved by the FDA, in his clinic in Houston Texas. Currently Dr. Burzynski has more than 90 treatment protocols, and uses multiple antineoplaston recipes. The individual treatment protocols differ significantly in some cases and depend on the respective type and size of the tumor. Currently there is probably no other form of therapy that deals with this important mechanism in the occurrence of cancer. The irony is that Dr. Burzynski found virtually no recognition for his discovery, which is worthy of a Nobel Prize. Instead for many years he was subjected to fierce attacks from the FDA and the Texas Medical Board. Today however his treatment is considered to be one of the most promising and most scientific non-conventional cancer therapies in the world. The therapy consists of an intravenous infusion (at the beginning – later capsules). The patient carries a miniature infusion pump in a small fanny pack that introduces antineoplastons into the chest (24-hours a day). This procedure is painless and does not limit the patient’s freedom of movement. As part of a study Dr. Burzynski used antineoplastons to treat 20 patients with an astrocytoma in an advanced stage. Approximately 80% had a positive reaction and some of them were still cancer-free after four years. Moreover animal studies in Japan showed that small doses of the synthetic antineoplaston A10 taken orally help prevent breast cancer, lung cancer, and liver cancer.Personal opinion: Dr. Burzynski was in Germany at my invitation in 1999, and gave several presentations in which he supported his therapy with many cases. Other cancer organizations have investigated successful cases and they have come to the same results as I have. I can maintain without doubt that Dr. Burzynski’s therapy should be viewed as the first option for brain tumors. Unfortunately the high initial costs of 2,000 to 3,000 Euro/month represent an excessively high hurdle and I hope that Dr. Burzynski’s therapy will finally be recognized so that the costs can be reduced significantly.